Wichita's obesity rate against Kansas, KanCare's June 2025 anti-obesity PA criteria, three published local price structures, and a low-income-population shortage designation.
Wichita's city-level adult obesity rate is 39.5% (BRFSS 2023, CDC PLACES) 1, against Kansas's statewide 35.9% 3. That is the gradient this page starts from: the state's largest city runs almost four points hotter than the state it anchors.
In a city of 400,993 inside a metro of 652,622 45, with 12.1% of residents uninsured 6, the practical question is what a month of treatment costs, and Wichita, unusually, has three clinics willing to publish an answer.
KanCare, Kansas Medicaid, has a working prior-authorization pathway for anti-obesity GLP-1s. KDHE's Criteria for Prior Authorization: Anti-Obesity Medications, with minor updates dated 6/1/2025, names liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound), and coverage is not diabetes-limited. As of that update, Wegovy and Zepbound no longer sit behind the older severe-obesity gate: KDHE's document states that section explicitly does not apply to Zepbound as of 4/1/24 or Wegovy as of 6/1/25 8.
Both now qualify under the general criteria alone, adult BMI at or above 30, or BMI at or above 27 plus one weight-related comorbidity from a broad list including hypertension, obstructive sleep apnea, PCOS, and depression, with a standard 28-week initial approval. Only Saxenda remains on the narrower BMI-40 pathway, or BMI 27 plus established cardiovascular disease and no diabetes history, on an eight-week high-cost-agent review cycle 8. Separately, Kansas has not adopted ACA Medicaid expansion as of 2026, leaving an estimated 28,000 Kansans in a coverage gap entirely, too much income for traditional Medicaid and too little for marketplace subsidies, independent of those PA criteria 9.
Everyday Wellness Wichita on East Central Avenue publishes the most transparent tier structure found in-city: Premium Care All-Inclusive at $315/month for semaglutide at all doses and $375/month low dose to $475/month high dose for tirzepatide, medication included. Cheaper Guided Care at $65/month and Independent Care at $25/month exclude medication and require a separate $150 initial visit, with individual vials also sold a la carte, semaglutide 2 to 2.5mL at $300 and tirzepatide 2mL at $400 or 4mL at $580, plus $10 lab draws (checked Aug 28, 2026) 10.
Meadow Aesthetics on East 21st North prices compounded injectable GLP-1s per eight-week initial block rather than monthly, semaglutide $450 and tirzepatide $700, roughly $244 and $380 on a monthly-equivalent basis, with dose-dependent follow-up visit pricing; it also offers oral Contrave, not a GLP-1, at $300 initial and $180/month maintenance 11. Shaw Plastic Surgery on North Greenwich Road lists semaglutide injections flatly at $240.00/month with weekly compounded dosing, without itemizing whether consults or labs are bundled, most insurance not accepted, FSA and HSA eligible, and no tirzepatide price published 12. Two other Wichita clinics, Evolve Healthcare and Wichita Medical Weight Loss, confirm they offer GLP-1s but publish no full pricing.
Astra's price is national and flat: $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 per year, identical in Wichita to every other city and at every dose.
Wichita is Kansas's largest city and the referral hub for south-central Kansas and northern Oklahoma, giving it stronger in-city specialist infrastructure than a typical tier-2 city. Ascension Via Christi runs a dedicated endocrinology clinic and a weight-management and bariatric-surgery program 13, Wesley Medical Center operates Wesley Bariatric 14, and the University of Kansas School of Medicine maintains a Wichita branch campus. These are hospital-affiliated programs built around insured, diagnosis-driven care, diabetes management and surgical candidacy, rather than fast self-pay GLP-1 prescribing. No dataset publishes a city-level endocrinologist-to-population ratio, so this is a qualitative finding, not a quantified access score.
Sedgwick County carries two active HRSA shortage designations, both scoped to the county's low-income population rather than the full geography: a Primary Care HPSA (ID 1205013008, score 14 of 26, Designated) and a Mental Health HPSA (ID 7205135374, score 17 of 25, Designated), both polygons covering downtown Wichita, with no active Dental HPSA at that point 7. Wichita is not a whole-geography shortage area; the documented gap is safety-net and sliding-scale capacity for low-income residents.
That is why the telehealth argument here is narrow and worth stating without overselling: the specialists exist, but a same-week, published-price, self-pay path to a GLP-1 prescription mostly does not. See the Kansas GLP-1 overview for statewide policy.
Astra treats patients in Kansas through state-licensed physicians.
Yes, for the Wichita clinics that publish a price. Astra's flat national rate is $68/mo for semaglutide and $118/mo for tirzepatide (12-month plans, $816/$1,416 per year). Everyday Wellness Wichita's all-inclusive plan runs $315/mo for semaglutide and $375-475/mo for tirzepatide — roughly 4.6x and 3.2-4x Astra's price. Meadow Aesthetics prices an 8-week compounded block at $450 (sema) / $700 (tirz), a monthly equivalent of about $244 and $380 — roughly 3.6x and 3.2x Astra's price. Shaw Plastic Surgery lists semaglutide flatly at $240/mo, about 3.5x Astra's price (Shaw doesn't publish a tirzepatide price). Two other Wichita clinics offering GLP-1s, Evolve Healthcare and Wichita Medical Weight Loss, don't publish pricing at all, so no comparison is possible there.
It can, with prior authorization. KDHE's Anti-Obesity Medications criteria (updated 6/1/2025) name both Wegovy (semaglutide) and Zepbound (tirzepatide) for weight-management coverage, and as of that update, both qualify under the general criteria alone — adult BMI≥30, or BMI≥27 plus one weight-related comorbidity such as hypertension, sleep apnea, PCOS, or depression. The older, stricter severe-obesity BMI≥40 gate no longer applies to either drug (a third GLP-1, Saxenda, still needs it). Separately, Kansas has not expanded Medicaid under the ACA, leaving an estimated 28,000 Kansans in a coverage gap outside KanCare eligibility entirely.
Partially. Sedgwick County, which contains Wichita, carries two active HRSA Health Professional Shortage Area designations — a Primary Care HPSA (ID 1205013008) and a Mental Health HPSA (ID 7205135374) — but both are scoped to the county's low-income population rather than the entire geography. The documented shortage is in safety-net and sliding-scale capacity specifically, not a citywide lack of providers.
Higher. Wichita's city-level adult obesity rate is 39.5% (CDC PLACES, BRFSS 2023 cycle) compared with 38.6% for Sedgwick County overall and 35.9% for Kansas statewide — a gap of 3.6 percentage points above the state average.
Wichita has more in-city specialist infrastructure than most tier-2 cities: Ascension Via Christi runs a dedicated Endocrinology clinic and a Weight Management/bariatric-surgery program, and Wesley Medical Center operates its own bariatric program, Wesley Bariatric. Both are hospital-affiliated programs built around insured, diagnosis-driven care rather than fast, self-pay GLP-1 prescribing — which is the access gap telehealth is built to close.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.